Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T84316
|
||||
Former ID |
TTDS00415
|
||||
Target Name |
Voltage-dependent calcium channel subunit alpha-2/delta-1
|
||||
Gene Name |
CACNA2D1
|
||||
Synonyms |
CACNL2A; CCHL2A; MHS3; Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1; Voltage-gated calcium channel subunit alpha-2/delta-1; CACNA2D1
|
||||
Target Type |
Successful
|
||||
Disease | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10: J40-J44, J47] | ||||
Cardiovascular disorder [ICD10: I00-I99] | |||||
Generalized anxiety disorder [ICD9: 300, 300.02, 311; ICD10: F32, F40-F42, F41.1] | |||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
Hypertension; Angina [ICD9: 401, 413; ICD10: I10-I16, I20] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Function |
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
|
||||
BioChemical Class |
Ca(2+) channel auxiliary subunit 2 1-4
|
||||
Target Validation |
T84316
|
||||
UniProt ID | |||||
Sequence |
MAAGCLLALTLTLFQSLLIGPSSEEPFPSAVTIKSWVDKMQEDLVTLAKTASGVNQLVDI
YEKYQDLYTVEPNNARQLVEIAARDIEKLLSNRSKALVRLALEAEKVQAAHQWREDFASN EVVYYNAKDDLDPEKNDSEPGSQRIKPVFIEDANFGRQISYQHAAVHIPTDIYEGSTIVL NELNWTSALDEVFKKNREEDPSLLWQVFGSATGLARYYPASPWVDNSRTPNKIDLYDVRR RPWYIQGAASPKDMLILVDVSGSVSGLTLKLIRTSVSEMLETLSDDDFVNVASFNSNAQD VSCFQHLVQANVRNKKVLKDAVNNITAKGITDYKKGFSFAFEQLLNYNVSRANCNKIIML FTDGGEERAQEIFNKYNKDKKVRVFTFSVGQHNYDRGPIQWMACENKGYYYEIPSIGAIR INTQEYLDVLGRPMVLAGDKAKQVQWTNVYLDALELGLVITGTLPVFNITGQFENKTNLK NQLILGVMGVDVSLEDIKRLTPRFTLCPNGYYFAIDPNGYVLLHPNLQPKPIGVGIPTIN LRKRRPNIQNPKSQEPVTLDFLDAELENDIKVEIRNKMIDGESGEKTFRTLVKSQDERYI DKGNRTYTWTPVNGTDYSLALVLPTYSFYYIKAKLEETITQARYSETLKPDNFEESGYTF IAPRDYCNDLKISDNNTEFLLNFNEFIDRKTPNNPSCNADLINRVLLDAGFTNELVQNYW SKQKNIKGVKARFVVTDGGITRVYPKEAGENWQENPETYEDSFYKRSLDNDNYVFTAPYF NKSGPGAYESGIMVSKAVEIYIQGKLLKPAVVGIKIDVNSWIENFTKTSIRDPCAGPVCD CKRNSDVMDCVILDDGGFLLMANHDDYTNQIGRFFGEIDPSLMRHLVNISVYAFNKSYDY QSVCEPGAAPKQGAGHRSAYVPSVADILQIGWWATAAAWSILQQFLLSLTFPRLLEAVEM EDDDFTASLSKQSCITEQTQYFFDNDSKSFSGVLDCGNCSRIFHGEKLMNTNLIFIMVES KGTCPCDTRLLIQAEQTSDGPNPCDMVKQPRYRKGPDVCFDNNVLEDYTDCGGVSGLNPS LWYIIGIQFLLLWLVSGSTHRLL |
||||
Drugs and Mode of Action | |||||
Drug(s) | Amlodipine | Drug Info | Approved | Hypertension; Angina | [537071], [542011] |
Diltiazem | Drug Info | Approved | Hypertension | [536619], [539449] | |
Lercanidipine | Drug Info | Approved | Hypertension | [536336] | |
Nitrendipine | Drug Info | Approved | Hypertension | [539478], [550669] | |
Pregabalin | Drug Info | Approved | Chronic obstructive pulmonary disease | [528162], [540884] | |
Imagabalin | Drug Info | Phase 3 | Generalized anxiety disorder | [531511] | |
Mirogabalin | Drug Info | Phase 3 | Cardiovascular disorder | [543055], [549169] | |
Lercanidipine | Drug Info | Phase 2 | Hypertension | [548460] | |
Inhibitor | (R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid | Drug Info | [527684] | ||
(S)-2-amino-2-cyclohexylacetic acid | Drug Info | [527946] | |||
(S)-2-amino-2-o-tolylacetic acid | Drug Info | [527946] | |||
(S)-2-amino-2-p-tolylacetic acid | Drug Info | [527946] | |||
(S)-2-amino-2-phenylpropanoic acid | Drug Info | [527946] | |||
(S)-2-amino-3-(benzylthio)propanoic acid | Drug Info | [527946] | |||
(S)-2-amino-3-cyclohexylpropanoic acid | Drug Info | [527946] | |||
(S)-2-amino-4-(benzylthio)butanoic acid | Drug Info | [527946] | |||
(S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid | Drug Info | [527684] | |||
(S)-phenylglycine | Drug Info | [527946] | |||
1-benzhydryl-4-(3,3-diphenylpropyl)piperazine | Drug Info | [530438] | |||
1-benzhydryl-4-(4,4-diphenylbutyl)piperazine | Drug Info | [530438] | |||
2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid | Drug Info | [530504] | |||
2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid | Drug Info | [530504] | |||
2-amino-2-(2,3-difluorophenyl)acetic acid | Drug Info | [527946] | |||
2-amino-2-(2,4-difluorophenyl)acetic acid | Drug Info | [527946] | |||
2-amino-2-(2-fluorophenyl)acetic acid | Drug Info | [527946] | |||
2-amino-2-(3-bromophenyl)acetic acid | Drug Info | [527946] | |||
2-amino-2-(3-chloro-4-fluorophenyl)acetic acid | Drug Info | [527946] | |||
2-amino-2-(3-chlorophenyl)acetic acid | Drug Info | [527946] | |||
2-amino-2-(thiophen-2-yl)acetic acid | Drug Info | [527946] | |||
2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid | Drug Info | [527946] | |||
3-(aminomethyl)-4-(furan-2-yl)butanoic acid | Drug Info | [527684] | |||
3-(aminomethyl)-4-(furan-3-yl)butanoic acid | Drug Info | [527684] | |||
3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid | Drug Info | [527684] | |||
3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid | Drug Info | [527684] | |||
3-Aminomethyl-5-methyl-hexanoic acid | Drug Info | [551273] | |||
4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(2-bromobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(2-cyanobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(2-methoxybenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(2-nitrobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3-bromobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3-chlorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3-cyanobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3-fluorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3-methoxybenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(3-nitrobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(4-bromobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(4-chlorobenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
4-(4-tert-butylbenzylthio)-2-aminobutanoic acid | Drug Info | [527946] | |||
ETHIONINE | Drug Info | [527946] | |||
Gababutin | Drug Info | [530504] | |||
N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine | Drug Info | [527016] | |||
N,4-dibenzhydrylpiperazine-1-carboxamide | Drug Info | [530438] | |||
NP-118809 | Drug Info | [530438] | |||
PD-144550 | Drug Info | [551273] | |||
Rac-2-amino-4-phenylbutanoic acid | Drug Info | [527946] | |||
Rac-2-amino-5-cyclohexylpentanoic acid | Drug Info | [527946] | |||
Trans-dimethyl gababutin | Drug Info | [530573] | |||
Blocker | Amlodipine | Drug Info | [536553], [536597] | ||
Diltiazem | Drug Info | [537595] | |||
Lercanidipine | Drug Info | [537620] | |||
Nitrendipine | Drug Info | [537276] | |||
Agonist | Imagabalin | Drug Info | [528162], [531511] | ||
Modulator | Mirogabalin | Drug Info | [528162], [532966] | ||
Pregabalin | Drug Info | [528162] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | MAPK signaling pathway | ||||
Cardiac muscle contraction | |||||
Adrenergic signaling in cardiomyocytes | |||||
Oxytocin signaling pathway | |||||
Hypertrophic cardiomyopathy (HCM) | |||||
Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
Dilated cardiomyopathy | |||||
PANTHER Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | ||||
miR-targeted genes in muscle cell - TarBase | |||||
miR-targeted genes in lymphocytes - TarBase | |||||
References | |||||
Ref 528162 | Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. Epub 2006 Apr 26. | ||||
Ref 531511 | Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. | ||||
Ref 536336 | Fixed-dose combination lercanidipine/enalapril. Drugs. 2007;67(1):95-106; discussion 107-8. | ||||
Ref 536619 | Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 2008 Feb;6(2):e26. | ||||
Ref 537071 | Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. Curr Med Res Opin. 2009 Jan;25(1):177-85. | ||||
Ref 539449 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2298). | ||||
Ref 539478 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2334). | ||||
Ref 540884 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5484). | ||||
Ref 542011 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6981). | ||||
Ref 543055 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8303). | ||||
Ref 548460 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025674) | ||||
Ref 527016 | Bioorg Med Chem Lett. 2004 Apr 19;14(8):1913-6.N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels. | ||||
Ref 527684 | Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. Epub 2005 Aug 15.Heteroaromatic side-chain analogs of pregabalin. | ||||
Ref 527946 | Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. Epub 2005 Dec 27.Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. | ||||
Ref 528162 | Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. Epub 2006 Apr 26. | ||||
Ref 530438 | Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. Epub 2009 Sep 11.Scaffold-based design and synthesis of potent N-type calcium channel blockers. | ||||
Ref 530504 | Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5. Epub 2009 Oct 25.Synthesis and in vivo evaluation of 3-substituted gababutins. | ||||
Ref 530573 | Bioorg Med Chem Lett. 2010 Jan 15;20(2):461-4. Epub 2009 Nov 27.Synthesis and in vivo evaluation of bicyclic gababutins. | ||||
Ref 531511 | Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. | ||||
Ref 532966 | Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61. | ||||
Ref 536553 | Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats. Eur J Pharmacol. 2008 Feb 2;580(1-2):201-13. Epub 2007 Nov 1. | ||||
Ref 536597 | A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94. | ||||
Ref 537276 | Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Apr 30. | ||||
Ref 537595 | Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24. Epub 2009 Jul 1. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.